Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region-Reference-Cited by-同舟云学术

Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region

Published:2023-01-24 Issue:1 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Han Kelong¹^ORCID,Ito Hiroshi²,Elston Robert³,Cremer Jennifer⁴,Hood Steve³,Paff Melanie¹,Theodore Dickens⁴

Affiliation:

1. GSK, Collegeville, Pennsylvania, USA

2. GSK K.K., Tokyo, Japan

3. GSK, Stevenage, United Kingdom

4. GSK, Durham, North Carolina, USA

Abstract

GSK3389404, an N-acetyl galactosamine-conjugated antisense oligonucleotide (ASO), was in clinical development for chronic hepatitis B (CHB) treatment. Few studies have examined ASOs in Asian participants.

Funder

GlaxoSmithKline

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00900-22

Reference24 articles.

1. World Health Organization. 2021. Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed 25 January 2021.

2. Hepatitis B infection in the general population of China: a systematic review and meta-analysis

3. World Health Organization. 2017. Global hepatitis report 2017. https://www.who.int/publications/i/item/9789241565455. Accessed 25 January 2021.

4. New Approaches to the Treatment of Chronic Hepatitis B

5. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides;Drugs in R&D;2024-06

2. The Coming Age of Antisense Oligos for the Treatment of Hepatic Ischemia/Reperfusion (IRI) and Other Liver Disorders: Role of Oxidative Stress and Potential Antioxidant Effect;Antioxidants;2024-05-31